The phase Ⅱ clinical trial of Seratia Marcescens Anticancer Vaccine (S311) for malignant pleural effusions

• Published in: Zhongguo fei ai za zhi 2001-07, Vol.4 (4)
• Main Authors: ZHU, Yunzhong, SHI, Heling, QIAN, Hao, HUANG, Wenxia, HONG, Zhuan, ZHANG, Yiping, XU, Nong, ZHANG, Li, LIU, Donggeng, TONG, Zhongsheng, LI, Shufen, ZHANG, Lijian, ZHENG, Wen
• Format: Article
• Language: Chinese
• Subjects: Cancer; Clinical trials; Vaccines
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/cjlc.v4i4.1813

目的 评价S311治疗癌性胸腔积液的疗效及毒副作用。方法 经胸穿或闭式引流抽净胸水后，胸腔注入S3110.32?mg，每周1次，连续3周，停药后观察1个月评价疗效。结果 241例患者完成胸腔注入S311治疗，总有效率92.1％。主要的不良反应为发热和胸痛，发生率分别为81.0％和52.2％。少数患者出现寒战、呼吸困难、恶心、呕吐，个别患者出现肝功能异常。结论 粘质沙雷氏菌菌苗(S311)是一种治疗癌性胸腔积液的有效药物。 Objective To evaluate the effect and adverse reactions of Seratia Marcescens Anticancer Vaccine ( S311) in the treatment of malignant pleural effusions. Methods 0. 32 mg of S311 was administered into intracavity once a week, for successive three weeks, after draining off the pleural cavity completely by thoracocentesis or chest drainage. Results Two hundred and forty-one patients with malignant effusions finished the arrangement of S311 therapy. The overall response rate was 92. 1%. The main adverse reactions were fever and pleuritic pain. Some patients had chill, dyspnea, nausea and vomiting. Liver dysfunction was observed in a few cases. Conclusion S311 is an effective drug for malignant pleural effusions.